Extended Data Fig. 3: Tumor specific CD4 T cells activate in TDLNs and rapidly acquire a TCF1+lin phenotype.
From: Differentiation fate of a stem-like CD4 T cell controls immunity to cancer
a) Representative I-AbGP66 tetramer staining and phenotype of GP66 + CD4 T cells in TDLNs one-week after TRAMPC1-GP inoculation. b-c) Phenotypic characterization of GP66 + CD4 T cells in TDLNs (b) or tumors (c) of 5-week TRAMPC1-GP bearing mice. Data are representative of 3–5 independent experiments (n > 5 mice for each marker). d) Representative CD44 and PD1 staining and phenotype of bulk PD1 + CD4 T cells in TDLNs of 5-week TRAMPC1-GP bearing mice. Summary plot shows the total numbers of activated (CD44 + PD1 +) CD4 T cell populations in each tissue. Kinetics plot shows the total number of activated CD4 T cells in each phenotype within TDLNs (n > = 5 mice for each timepoint for each individual experiment). e) Frequency of PD1 + CD4 T cells expressing FOXP3 in TDLNs 1-week after tumor inoculation or secondary lymphoid tissues 8-days after LCMV Armstrong infection. Data are representative of 2 independent experiments (n = 5–7 mice per group for each timepoint). f-g) Phenotype of GP66+ (f) or bulk PD1+ (g) CD4 T cells 12-days after B16-GP inoculation in TDLNs. Data are representative of 2 independent experiments (n = 10). h) Representative CD44 and PD1 staining, and phenotype of bulk PD1 + CD4 T cells in TDLNs of day 14 MC38 bearing mice. Data are representative of 2 independent experiments (n = 11). i) Representative TCF1 and BCL6 staining in GP66 + CD4 T cells on D8 LCMV Armstrong infected mice in the spleen. Summary plot shows the frequency of virus specific CD4 T cells in each phenotype. Data are representative of 2 independent experiments (n = 10). j) Phenotype of endogenous CD44 + PD1 + CD4 T cells in subcutaneous D21–28 RENCA-HA TDLNs and tumor (n = 8–12 mice). k) Phenotype of PD1 + CD4 T cells in orthotopic RENCA-HA-Luciferase in tumors 15-days after orthotopic implant (n = 9 mice).
